Kyverna Therapeutics, Inc.
For the period ended Jun 30, 2026. Filed Aug 11, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2026 · Filed Aug 11, 2026
KYTX$5.08-1.7%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · AdditionalPaid-in · Accumulated · AccumulatedOtherComprehensive · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Income (Loss) | Equity | |
| Balance as of December 31, 2025 | 60,389,893 | $1 | $657,005 | $(424,827) | $97 | $232,276 |
| Common shares issued upon exercise of options | 90,735 | — | 243 | — | — | 243 |
| Issuance of common stock upon settlement of restricted stock units, net of shares withheld for taxes | 51,872 | — | (189) | — | — | (189) |
| Stock-based compensation expense | — | — | 3,171 | — | — | 3,171 |
| Net loss | — | — | — | (39,728) | — | (39,728) |
| Unrealized loss on available-for-sale marketable securities, net | — | — | — | — | (193) | (193) |
| Balance as of March 31, 2026 | 60,532,500 | $1 | $660,230 | $(464,555) | $(96) | $195,580 |
| Issuance of common stock under ATM Facility, net of sales agent's fees and issuance costs of $332 | 426,038 | — | 3,362 | — | — | 3,362 |
| Common shares issued upon exercise of options | 429,616 | — | 1,653 | — | — | 1,653 |
| Issuance of common stock upon settlement of restricted stock units, net of shares withheld for taxes | 182,093 | — | (188) | — | — | (188) |
| Stock-based compensation expense | — | — | 3,507 | — | — | 3,507 |
| Net loss | — | — | — | (38,319) | — | (38,319) |
| Unrealized loss on available-for-sale marketable securities, net | — | — | — | — | (46) | (46) |
| Balance as of June 30, 2026 | 61,570,247 | $1 | $668,564 | $(502,874) | $(142) | $165,549 |
| Balance as of December 31, 2024 | 43,214,918 | $— | $530,002 | $(263,520) | $105 | $266,587 |
| Common shares issued upon exercise of options | 3,955 | — | 3 | — | — | 3 |
| Stock-based compensation expense | — | — | 2,161 | — | — | 2,161 |
| Net loss | — | — | — | (44,635) | — | (44,635) |
| Unrealized loss on available-for-sale marketable securities, net | — | — | — | — | (106) | (106) |
| Balance as of March 31, 2025 | 43,218,873 | $— | $532,166 | $(308,155) | $(1) | $224,010 |
| Stock-based compensation expense | — | — | 2,518 | — | — | 2,518 |
| Issuance of common stock upon settlement of restricted stock units, net of shares withheld for taxes | 26,057 | — | (51) | — | — | (51) |
| Net loss | — | — | — | (42,081) | — | (42,081) |
| Unrealized loss on available-for-sale marketable securities, net | — | — | — | — | (19) | (19) |
| Balance as of June 30, 2025 | 43,244,930 | $— | $534,633 | $(350,236) | $(20) | $184,377 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.